Agreement - July 14, 2026
Prolight signs development agreement with BRAINBox
Prolight Diagnostics has announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions.
Collaboration - May 19, 2025
Elypta is main partner in European hereditary multi-cancer screening project
Elypta has announced its role as a main partner in PREDI-LYNCH, a European initiative aimed at transforming early cancer detection for individuals with Lynch Syndrome (LS).
Drug Development Pharma - March 24, 2025
New findings about Elypta’s urine test in kidney cancer follow-up
Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.
Business article - March 12, 2025
Boule Diagnostics closes BM950 project and announces new portfolio strategy
Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.
New Market - February 10, 2025
Boule Diagnostics enters distribution agreement
Boule Diagnostics has entered into an exclusive distribution agreement with VitalScientific for the US market.
Financing - January 14, 2025
MONCYTE Health joins EUR 7 million project
MONCYTE Health has been selected to join a 4-year Horizon funded project as a core industrial partner.
